<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215393</url>
  </required_header>
  <id_info>
    <org_study_id>KH906-40101</org_study_id>
    <nct_id>NCT04215393</nct_id>
  </id_info>
  <brief_title>An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization</brief_title>
  <official_title>An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of Conbercept Eye Drops in Patients With Corneal Neovascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first stage of this study will evaluates the tolerability of different concentrations of
      Conbercept eye drop to patients with corneal neovascularization.

      The second stage of this study will evaluate the effectiveness of conbercept eye drop
      initially.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular and Systemic Safety: occurrence of ocular and systemic adverse events</measure>
    <time_frame>day 14</time_frame>
    <description>The occurrence of ocular and systemic adverse events was closely monitored over the course of this study. Ocular adverse events were monitored through complete ocular examinations. Systemic adverse events were identified with physical examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Size and Extent of Corneal Neovascularization Will be Measured by Computerized Image Analysis of Corneal Photographs Taken Throughout the Study</measure>
    <time_frame>day 14 and day 28</time_frame>
    <description>The efficacy of KH906 in the treatment of corneal NV was evaluated by comparing corneal photographs taken at baseline with corneal photographs taken at the follow-up visits. Percent change from baseline was measured.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Corneal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Conbercept eye drop (0.1mg/ mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 0.1mg/mL Conbercept eye drop 4 times a day, one drop at a time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conbercept eye drop (0.5mg/ mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 0.5mg/mL Conbercept eye drop 4 times a day, one drop at a time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conbercept eye drop (1.0mg/ mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 1.0mg/mL Conbercept eye drop 4 times a day, one drop at a time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept eye drop</intervention_name>
    <description>In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.</description>
    <arm_group_label>Conbercept eye drop (0.1mg/ mL)</arm_group_label>
    <arm_group_label>Conbercept eye drop (0.5mg/ mL)</arm_group_label>
    <arm_group_label>Conbercept eye drop (1.0mg/ mL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In the second stage, subjects will be receive Conbercept eys drop or a placebo.</description>
    <arm_group_label>Conbercept eye drop (0.5mg/ mL)</arm_group_label>
    <arm_group_label>Conbercept eye drop (1.0mg/ mL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed the informed consent form, volunteered to participate in the trial and followed
             up according to the protocol.

          -  Ages from 18 to 75,male or female.

          -  Superficial or deep neovascularization induced by trauma/chemical
             burn/inflammation/corneal transplantation.

        Exclusion Criteria:

          -  Subjects who had significant defect in the corneal epithelium.

          -  Study eye had been injected of anti-vegf drugs within 3 months before screening

          -  Study eye was performed surgery (except keratoplasty) within 3 months prior screening,
             or eye surgery was planned during this trial period.

          -  Oral glucocorticoid administration within 1 month prior screening (except for duration
             less than 7 days)

          -  Systemic use of anti-vegf drugs within 45 days prior to screening.

          -  Have history of abnormal coagulation, such as end-stage liver disease, or are taking
             anticoagulants（except aspirin）.

          -  Uncontrolled clinical problems such as canner etc..

          -  Unable or unwilling to use effective contraception.

          -  Positive blood tests for pregnancy (female subjects)

          -  Participated in drug clinical trials within 3 months before the first administration.

          -  The researchers think the participants were not suitable for this trail.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deng Yingping</last_name>
    <phone>18980601736</phone>
    <email>Dyp558@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deng yingping</last_name>
      <email>Dyp588@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

